JP2007504863A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504863A5
JP2007504863A5 JP2006525566A JP2006525566A JP2007504863A5 JP 2007504863 A5 JP2007504863 A5 JP 2007504863A5 JP 2006525566 A JP2006525566 A JP 2006525566A JP 2006525566 A JP2006525566 A JP 2006525566A JP 2007504863 A5 JP2007504863 A5 JP 2007504863A5
Authority
JP
Japan
Prior art keywords
app
binding
peptide
antibody
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504863A (ja
JP4509113B2 (ja
Filing date
Publication date
Priority claimed from AT0144403A external-priority patent/AT413336B/de
Application filed filed Critical
Publication of JP2007504863A publication Critical patent/JP2007504863A/ja
Publication of JP2007504863A5 publication Critical patent/JP2007504863A5/ja
Application granted granted Critical
Publication of JP4509113B2 publication Critical patent/JP4509113B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006525566A 2003-09-12 2004-09-13 アフェレーシス装置 Expired - Fee Related JP4509113B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0144403A AT413336B (de) 2003-09-12 2003-09-12 Apherese-vorrichtung
PCT/AT2004/000311 WO2005025651A1 (de) 2003-09-12 2004-09-13 Apherese-vorrichtung

Publications (3)

Publication Number Publication Date
JP2007504863A JP2007504863A (ja) 2007-03-08
JP2007504863A5 true JP2007504863A5 (cg-RX-API-DMAC7.html) 2010-03-25
JP4509113B2 JP4509113B2 (ja) 2010-07-21

Family

ID=34280361

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525566A Expired - Fee Related JP4509113B2 (ja) 2003-09-12 2004-09-13 アフェレーシス装置

Country Status (15)

Country Link
US (2) US7935252B2 (cg-RX-API-DMAC7.html)
EP (1) EP1663347B1 (cg-RX-API-DMAC7.html)
JP (1) JP4509113B2 (cg-RX-API-DMAC7.html)
CN (1) CN100556472C (cg-RX-API-DMAC7.html)
AT (2) AT413336B (cg-RX-API-DMAC7.html)
AU (1) AU2004271651B2 (cg-RX-API-DMAC7.html)
CA (1) CA2538305C (cg-RX-API-DMAC7.html)
CY (1) CY1107911T1 (cg-RX-API-DMAC7.html)
DE (1) DE502004005851D1 (cg-RX-API-DMAC7.html)
DK (1) DK1663347T3 (cg-RX-API-DMAC7.html)
ES (1) ES2298789T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20080090T3 (cg-RX-API-DMAC7.html)
PL (1) PL1663347T3 (cg-RX-API-DMAC7.html)
PT (1) PT1663347E (cg-RX-API-DMAC7.html)
WO (1) WO2005025651A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT501621A1 (de) * 2005-03-15 2006-10-15 Mattner Frank Dr Zusammensetzungen zur verwendung bei der vorbeugung und behandlung der alzheimer- erkrankung
ES2332846B1 (es) * 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
JP2011508622A (ja) * 2007-12-21 2011-03-17 ジーイー・ヘルスケア・バイオ−サイエンシズ・アーベー 化学的に活性化された固相支持体材料の滅菌のための方法
EP2320987A1 (en) * 2008-07-29 2011-05-18 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
CA2748561C (en) * 2008-12-22 2016-11-01 Kaneka Corporation A.beta. remover, a.beta. removing apparatus and a.beta. removal system
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
EP2497828A1 (en) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
PT2579042E (pt) 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
US9717841B2 (en) 2012-09-11 2017-08-01 Gary L. McNeil Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
AU2015286606A1 (en) 2014-07-10 2017-01-12 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
CN107074925B (zh) 2014-07-10 2021-08-24 阿费里斯股份公司 用于预防和/或治疗亨廷顿氏病的物质和方法
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
GB201904810D0 (en) * 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57103649A (en) * 1980-12-18 1982-06-28 Asahi Chemical Ind Sterilized gamma-globulin fixing column
EP0236509B1 (en) 1985-09-19 1993-02-10 Toray Industries, Inc. B2-microglobulin-removing column
JPH01171638A (ja) * 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドa蛋白用吸着体
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US5216127A (en) * 1987-11-20 1993-06-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Adsorbent for serum amyloid protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
JPH06104122A (ja) 1992-09-21 1994-04-15 Matsushita Electric Ind Co Ltd ロータリートランス
AU691297B2 (en) * 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
DE19515554C2 (de) * 1995-04-27 1999-06-17 Braun Melsungen Ag Verwendung eines Mittels und Vorrichtung zur simultanen extrakorporalen Elimination von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus Vollblut oder/und Blutplasma
US5868936A (en) * 1996-06-20 1999-02-09 Baxter International Inc. Affinity membrane system and method of using same
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
TWI238251B (en) * 2000-07-13 2005-08-21 Anawrhta Biotech Co Ltd In-vitro adsorbing device using immunity
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
AU2003303198A1 (en) * 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Similar Documents

Publication Publication Date Title
JP2007504863A5 (cg-RX-API-DMAC7.html)
JP2008506665A5 (cg-RX-API-DMAC7.html)
CA2577332C (en) Combination therapy for the prevention or treatment of alzheimer's disease as well as kit therefor
TR200001795T2 (tr) 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı.
ATE430569T1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
CN101420992B (zh) 用于体外处理含粒子的液体的可再生过滤器及其应用
JP2010507432A5 (cg-RX-API-DMAC7.html)
SE0401253L (sv) Bärbar anordning för kontinuerlig venovenös hemofiltration/dialys
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
CA2538305A1 (en) Apheresis device
EP1569691A4 (en) DISTRIBUTION OF PHARMACEUTICAL AGENTS OVER THE HUMAN INSULIN RECEPTOR
DE60142500D1 (de) Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon
EP2277570A3 (en) Medical devices containing rapamycin analogs
NL1024314A1 (nl) Geïntegreerde beeldregistratie voor cardische magnetische-resonantie-doorbloedingsdata.
DK1633395T3 (da) Funktionelt rekonstituerede virusmembraner indeholdende adjuvans
JP2007513079A5 (cg-RX-API-DMAC7.html)
JP2004517824A5 (cg-RX-API-DMAC7.html)
EE05168B1 (et) N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
EE200100662A (et) Hüübimistegurit pärssiv ühend, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaatning raviotstarbeline kasutamine
FR2819810B1 (fr) Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
NO20010029D0 (no) Anvendelse av cystein-derivater for fremstilling av en medisin for behandling av patologier som stammer fra dannelse av heterotrimert G-protein
NO20070831L (no) Middel for aktivering av tilfriskning fra dysfunksjon etter starten av sentralnevrologisk sykdom.
JP6703973B2 (ja) β2mタンパク質の治療的使用
DK1418905T3 (da) Terapeutisk middel til depletering af en uönsket proteinpopulation fra plasma
JP2004101392A5 (cg-RX-API-DMAC7.html)